Loading...
XSHE300254
Market cap306mUSD
Dec 27, Last price  
9.00CNY
1D
3.45%
1Q
7.40%
Jan 2017
-53.34%
IPO
-25.09%
Name

Shanxi C&Y Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300254 chart
P/E
88.70
P/S
2.80
EPS
0.10
Div Yield, %
0.00%
Shrs. gr., 5y
3.03%
Rev. gr., 5y
-6.80%
Revenues
799m
-3.58%
203,666,798203,666,798243,618,734319,552,530310,780,744361,500,206513,510,739653,655,235683,934,855746,076,863938,927,9861,136,495,6671,131,801,411848,072,527930,374,948828,997,054799,305,103
Net income
25m
13,035,04413,035,04428,900,35647,983,62235,344,03525,801,04627,112,43940,997,49722,900,02930,147,70721,673,4197,241,0805,296,78800025,195,587
CFO
38m
-49.50%
0105,550,37552,032,4634,750,02235,051,20580,581,53382,191,77715,443,10841,650,14040,103,87838,440,74369,631,646096,921,05874,876,11637,814,367
Dividend
Jul 11, 20190.02 CNY/sh
Earnings
Apr 09, 2025

Profile

ShanXi C&Y Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China, the United States, Hong Kong, and internationally. It offers products for pregnant women and babies; urinary system products; anti-infection products; traditional Chinese medicines; and dermatology products, as well as tea bags. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to Shanxi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Shanxi C&Y Pharmaceutical Group Co., LTD. was founded in 2005 and is headquartered in Shanghai, China.
URL
http://www.cy-pharm.com/
IPO date
Aug 19, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
799,305
-3.58%
828,997
-10.90%
930,375
9.70%
Cost of revenue
605,330
756,379
850,351
Unusual Expense (Income)
NOPBT
193,975
72,618
80,024
NOPBT Margin
24.27%
8.76%
8.60%
Operating Taxes
6,553
7,970
9,068
Tax Rate
3.38%
10.98%
11.33%
NOPAT
187,422
64,647
70,957
Net income
25,196
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
67,432
407,937
190,605
Long-term debt
177,670
216,493
44,923
Deferred revenue
8,607
8,867
10,921
Other long-term liabilities
17,399
10,124
291,310
Net debt
11,376
195,344
(43,538)
Cash flow
Cash from operating activities
37,814
74,876
96,921
CAPEX
(33,916)
Cash from investing activities
72,104
Cash from financing activities
(241,772)
112,564
FCF
298,658
101,242
153,389
Balance
Cash
132,004
263,946
107,255
Long term investments
101,723
165,141
171,811
Excess cash
193,761
387,636
232,547
Stockholders' equity
419,918
414,330
401,098
Invested Capital
836,893
940,679
1,019,699
ROIC
21.09%
6.60%
6.55%
ROCE
17.99%
5.31%
6.19%
EV
Common stock shares outstanding
241,619
237,069
227,971
Price
9.63
42.25%
6.77
-22.09%
8.69
26.12%
Market cap
2,326,787
44.97%
1,604,959
-18.99%
1,981,067
34.85%
EV
2,516,462
1,955,062
2,092,703
EBITDA
252,500
137,403
146,952
EV/EBITDA
9.97
14.23
14.24
Interest
33,293
46,063
49,171
Interest/NOPBT
17.16%
63.43%
61.45%